CA1239587A - Compose d'acides gras pour abaisser les taux de cholesterol et de triglycerides sanguins - Google Patents

Compose d'acides gras pour abaisser les taux de cholesterol et de triglycerides sanguins

Info

Publication number: CA1239587A
Authority: CA; Canada
Prior art keywords: acid; accordance; cis; composition; component
Prior art date: 1983-10-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000465531A

Other languages

English (en)

Inventor

David Rubin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Century Laboratories Inc

Original Assignee

Century Laboratories Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-10-24

Filing date

1984-10-16

Publication date

1988-07-26

1983-10-24 Priority claimed from US06/545,349 external-priority patent/US4526902A/en

1984-10-16 Application filed by Century Laboratories Inc filed Critical Century Laboratories Inc

1988-07-26 Application granted granted Critical

1988-07-26 Publication of CA1239587A publication Critical patent/CA1239587A/fr

Status Expired legal-status Critical Current

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 37
235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 34
239000000194 fatty acid Substances 0.000 title claims abstract description 34
229930195729 fatty acid Natural products 0.000 title claims abstract description 34
150000004665 fatty acids Chemical class 0.000 title claims abstract description 34
239000000203 mixture Substances 0.000 title claims abstract description 30
210000004369 blood Anatomy 0.000 title claims abstract description 8
239000008280 blood Substances 0.000 title claims abstract description 8
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims abstract description 7
LEIXEEFBKOMCEQ-AFJQJTPPSA-N (9z,12z)-heptadeca-9,12-dienoic acid Chemical compound CCCC\C=C/C\C=C/CCCCCCCC(O)=O LEIXEEFBKOMCEQ-AFJQJTPPSA-N 0.000 claims abstract description 20
235000013305 food Nutrition 0.000 claims abstract description 10
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims abstract description 9
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 4
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract 5
HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims abstract 3
230000009467 reduction Effects 0.000 claims description 8
235000021122 unsaturated fatty acids Nutrition 0.000 claims description 6
150000004670 unsaturated fatty acids Chemical class 0.000 claims description 6
239000000306 component Substances 0.000 claims 12
SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 claims 4
HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 claims 4
229940000425 combination drug Drugs 0.000 claims 1
MBMBGCFOFBJSGT-SFGLVEFQSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O MBMBGCFOFBJSGT-SFGLVEFQSA-N 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
238000004440 column chromatography Methods 0.000 abstract description 9
235000013310 margarine Nutrition 0.000 abstract description 6
239000003264 margarine Substances 0.000 abstract description 6
239000003921 oil Substances 0.000 abstract description 6
235000019197 fats Nutrition 0.000 abstract description 4
239000008162 cooking oil Substances 0.000 abstract description 3
229960005135 eicosapentaenoic acid Drugs 0.000 abstract description 2
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 1
230000002083 iodinating effect Effects 0.000 abstract 1
230000001035 methylating effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 description 14
238000011282 treatment Methods 0.000 description 12
235000012000 cholesterol Nutrition 0.000 description 10
230000026045 iodination Effects 0.000 description 10
238000006192 iodination reaction Methods 0.000 description 10
230000008569 process Effects 0.000 description 10
239000002253 acid Substances 0.000 description 9
230000000694 effects Effects 0.000 description 7
235000021323 fish oil Nutrition 0.000 description 7
150000003180 prostaglandins Chemical class 0.000 description 7
238000000926 separation method Methods 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
229940094443 oxytocics prostaglandins Drugs 0.000 description 6
239000000243 solution Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 5
238000007127 saponification reaction Methods 0.000 description 5
239000007858 starting material Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
-1 PGÆ3 Chemical class 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
235000012716 cod liver oil Nutrition 0.000 description 4
239000003026 cod liver oil Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
IZFHEQBZOYJLPK-UHFFFAOYSA-N dihydrolipoic acid Chemical compound OC(=O)CCCCC(S)CCS IZFHEQBZOYJLPK-UHFFFAOYSA-N 0.000 description 4
238000009472 formulation Methods 0.000 description 4
229960004488 linolenic acid Drugs 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
229960002986 dinoprostone Drugs 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000003925 fat Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
QFWWSZLGTLNVMS-UHFFFAOYSA-N acetic acid;ethoxyethane;hexane Chemical compound CC(O)=O.CCOCC.CCCCCC QFWWSZLGTLNVMS-UHFFFAOYSA-N 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
229940114079 arachidonic acid Drugs 0.000 description 2
235000021342 arachidonic acid Nutrition 0.000 description 2
235000014121 butter Nutrition 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
229940013317 fish oils Drugs 0.000 description 2
238000000703 high-speed centrifugation Methods 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000003119 painkilling effect Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229960001866 silicon dioxide Drugs 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
238000003756 stirring Methods 0.000 description 2
235000009434 Actinidia chinensis Nutrition 0.000 description 1
244000298697 Actinidia deliciosa Species 0.000 description 1
235000009436 Actinidia deliciosa Nutrition 0.000 description 1
241000024188 Andala Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000273930 Brevoortia tyrannus Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
241001414890 Delia Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
244000028344 Primula vulgaris Species 0.000 description 1
235000016311 Primula vulgaris Nutrition 0.000 description 1
241000220317 Rosa Species 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
VAYROLOSUUAGTR-UHFFFAOYSA-N [Ag].[I] Chemical compound [Ag].[I] VAYROLOSUUAGTR-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000003139 biocide Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000004927 clay Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000036570 collagen biosynthesis Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000005831 deiodination reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940096118 ella Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000004452 microanalysis Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
239000005445 natural material Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000021590 normal diet Nutrition 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 1
238000011160 research Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
125000005457 triglyceride group Chemical group 0.000 description 1
OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
- C11C1/025—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by saponification and release of fatty acids
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/005—Splitting up mixtures of fatty acids into their constituents
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Nutrition Science (AREA)
Mycology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Edible Oils And Fats (AREA)

CA000465531A 1983-10-24 1984-10-16 Compose d'acides gras pour abaisser les taux de cholesterol et de triglycerides sanguins Expired CA1239587A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US54535083A	1983-10-24	1983-10-24
US545,349		1983-10-24
US545,350		1983-10-24
US06/545,349 US4526902A (en)	1983-10-24	1983-10-24	Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions

Publications (1)

Publication Number	Publication Date
CA1239587A true CA1239587A (fr)	1988-07-26

Family

ID=27067902

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000465531A Expired CA1239587A (fr)	1983-10-24	1984-10-16	Compose d'acides gras pour abaisser les taux de cholesterol et de triglycerides sanguins

Country Status (7)

Country	Link
CA (1)	CA1239587A (fr)
CH (1)	CH661209A5 (fr)
DE (1)	DE3438630A1 (fr)
FR (1)	FR2553662B1 (fr)
GB (1)	GB2148713B (fr)
IT (1)	IT1178170B (fr)
SE (1)	SE462701B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007063158A2 (fr)	2005-11-30	2007-06-07	La Morella Nuts, S.A.	Aliment fonctionnel a effets positifs dans la prevention de maladies cardiovasculaires

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8507058D0 (en) *	1985-03-19	1985-04-24	Efamol Ltd	Pharmaceutical & dietary compositions
US4792418A (en) *	1985-08-14	1988-12-20	Century Laboratories, Inc.	Method of extraction and purification of polyunsaturated fatty acids from natural sources
GB8601915D0 (en) *	1986-01-27	1986-03-05	Efamol Ltd	Pharmaceutical compositions
DE3603000A1 (de) *	1986-01-31	1987-08-06	Milupa Ag	Neue polyensaeure-reiche fettmischung und deren verwendung bei der herstellung von saeuglingsnahrungen
DE3615710A1 (de) *	1986-05-09	1987-11-26	Hoechst Ag	Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen
HU204199B (en) *	1987-03-18	1991-12-30	Caola Kozmetikai	Process for producing pharmaceutical compositions containing unsaturated fatty acids and selenium as active components
GB8715914D0 (en) *	1987-07-07	1987-08-12	Efamol Ltd	Treatment of cerabral disorders
US4843095A (en) *	1987-08-07	1989-06-27	Century Laboratories, Inc.	Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
FR2623692B1 (fr) *	1987-11-30	1991-05-03	Vernin Jean Gilles	Nouvelle huile dietetique
HU210122B (en) *	1988-03-23	1995-02-28	Biorex Kutato Fejlesztoe Kft	Process for production of composition against thromboembolytic conditions of circulating system and heart
GB8813766D0 (en) *	1988-06-10	1988-07-13	Efamol Holdings	Essential fatty acid compositions
GB8819110D0 (en) *	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
US5116871A (en) *	1988-09-13	1992-05-26	Efamol Holdings Plc	Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
DK162621C (da) *	1989-04-27	1992-04-13	Jon Katborg	Skumformigt fedtstofprodukt og fremgangsmaade til fremstilling af samme
DE3924607A1 (de) *	1989-07-21	1991-01-24	Singer Peter Dr Sc Med	Diaetetisches nahrungs- oder genussmittel
DE19503993A1 (de) *	1995-02-08	1996-08-14	Johann Friedrich Dr Med Desaga	Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
WO1996040106A2 (fr) *	1995-06-07	1996-12-19	Martek Biosciences Corporation	Procede visant a maitriser la teneur en acides gras hautement insatures de divers tissus
AU731692C (en)	1996-10-11	2001-10-11	Scarista Limited	Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
GB9901809D0 (en)	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE19903095C2 (de) *	1999-01-27	2003-05-22	Nutrinova Gmbh	Gewinnung von gamma-Linolensäure aus Protozoen der Gattung Colpidium
SE0202188D0 (sv)	2002-07-11	2002-07-11	Pronova Biocare As	A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP2295529B2 (fr)	2002-07-11	2022-05-18	Basf As	Procédé de diminution des polluants environnementaux dans une huile ou une graisse et produit d'alimentation pour poissons
US6846942B2 (en)	2003-05-20	2005-01-25	David Rubin	Method for preparing pure EPA and pure DHA
ITMI20040069A1 (it)	2004-01-21	2004-04-21	Tiberio Bruzzese	Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
EP3187182B1 (fr)	2008-09-02	2021-03-03	Amarin Pharmaceuticals Ireland Limited	Compositions pharmaceutiques contenant de l'acide eicosapentaénoïque et de l'acide nicotinique, et leurs procédés d'utilisation
RU2505292C2 (ru)	2009-02-10	2014-01-27	Амарин Фармасьютикалз Айрлэнд Лимитед	Способы лечения гипертриглицеридемии
MX377553B (es)	2009-04-29	2025-03-10	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
CN107233337A (zh)	2009-04-29	2017-10-10	阿马里纳药物爱尔兰有限公司	含有epa和心血管剂的药物组合物以及使用其的方法
BRPI1011883A2 (pt)	2009-06-15	2016-09-13	Amarin Pharma Inc	uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
EP2464240A1 (fr) *	2009-08-10	2012-06-20	K.D. Pharma Bexbach GMBH	Procédé de fractionnement d'acide phytanique, produits d'acide gras et leur utilisation
NZ599061A (en)	2009-09-23	2014-05-30	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ744990A (en)	2010-11-29	2019-10-25	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
WO2013070735A1 (fr)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Méthodes de traitement de l'hypertriglycéridémie
EP2800469B1 (fr)	2012-01-06	2021-08-25	Amarin Pharmaceuticals Ireland Limited	Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet
US9603826B2 (en)	2012-06-29	2017-03-28	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (fr)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (fr)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Procédés de réduction ou de prévention de l'oxydation des ldl petites et denses ou des acides gras polyinsaturés membranaires
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en)	2017-05-19	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr)	2018-09-24	2020-09-02	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (fr)	2019-11-12	2021-05-20	Amarin Pharmaceuticals Ireland Limited	Procedes de reduction du risque d'evenements cardiovasculaires chez un sujet souffrant d'une fibrillation auriculaire et/ou d'un flutter auriculaire
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1476624A (en) *	1973-05-30	1977-06-16	Cepbepe	Tranquiliser medicaments
GB2033745B (en) *	1978-05-26	1983-08-17	Wellcome Found	Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
GB1604554A (en) *	1978-05-26	1981-12-09	Dyerberg J	Pharmaceutical and food formulations
AU527784B2 (en) *	1978-05-26	1983-03-24	Bang, Hans Olaf Dr.	Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
DE3152174A1 (de) *	1980-06-27	1982-08-12	Nippon Oils & Fats Co Ltd	Thrombosis-prophylatic and curing agent
US4377526A (en) *	1981-05-15	1983-03-22	Nippon Suisan Kaisha, Ltd.	Method of purifying eicosapentaenoic acid and its esters
GB8302708D0 (en) *	1983-02-01	1983-03-02	Efamol Ltd	Pharmaceutical and dietary composition
FR2548021B1 (fr) *	1983-06-29	1986-02-28	Dick P R	Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8319073D0 (en) *	1983-07-14	1983-08-17	Efamol Ltd	Fatty acid compositions

1984
- 1984-10-16 CA CA000465531A patent/CA1239587A/fr not_active Expired
- 1984-10-22 DE DE19843438630 patent/DE3438630A1/de not_active Ceased
- 1984-10-23 GB GB08426765A patent/GB2148713B/en not_active Expired
- 1984-10-23 FR FR8416171A patent/FR2553662B1/fr not_active Expired
- 1984-10-23 CH CH5070/84A patent/CH661209A5/de not_active IP Right Cessation
- 1984-10-24 IT IT49063/84A patent/IT1178170B/it active
- 1984-10-24 SE SE8405308A patent/SE462701B/sv not_active IP Right Cessation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007063158A2 (fr)	2005-11-30	2007-06-07	La Morella Nuts, S.A.	Aliment fonctionnel a effets positifs dans la prevention de maladies cardiovasculaires

Also Published As

Publication number	Publication date
DE3438630A1 (de)	1985-05-02
FR2553662A1 (fr)	1985-04-26
SE8405308L (sv)	1985-04-25
IT8449063A1 (it)	1986-04-24
FR2553662B1 (fr)	1989-06-09
SE462701B (sv)	1990-08-20
CH661209A5 (de)	1987-07-15
GB2148713B (en)	1987-04-23
IT8449063A0 (it)	1984-10-24
GB8426765D0 (en)	1984-11-28
IT1178170B (it)	1987-09-09
GB2148713A (en)	1985-06-05
SE8405308D0 (sv)	1984-10-24

Legal Events

Date	Code	Title	Description
2005-07-26	MKEX	Expiry
2023-05-26	MKEX	Expiry	Effective date: 20050726

Publication	Publication Date	Title
US4526902A (en)	1985-07-02	Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB2148713A (en)	1985-06-05	Pharmaceutical composition and food product comprising higher fatty acids
US4843095A (en)	1989-06-27	Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
KR0129666B1 (ko)	1998-04-09	필수지방산 조성물
KR0126286B1 (ko)	1997-12-26	지방산 조성물
AU666747B2 (en)	1996-02-22	Fatty acid treatment
CA1261274A (fr)	1989-09-26	Compositions pharmaceutiques et dietetiques
US5670540A (en)	1997-09-23	Triglycerides of fatty acids
KR100274727B1 (ko)	2000-12-15	지방산 조성물
US4776984A (en)	1988-10-11	Process for the enrichment with Δ6 fatty acids of a mixture of fatty acids
SK14502003A3 (en)	2004-10-05	Coenzyme Q and eicosapentaenoic acid
NZ513093A (en)	2003-02-28	Use of the essential fatty acids eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester in the prevention of cardiovascular events
JPS6296422A (ja)	1987-05-02	子宮内膜増殖症予防または治療用組成物の製造方法およびその来成物を用いる前記増殖症の予防または治療方法
CN1096197A (zh)	1994-12-14	含不饱和脂肪酸酯类的组合物
JPH0733655A (ja)	1995-02-03	医薬組成物
TNSN92008A1 (fr)	1993-06-08	Steroides-esters nouveaux
JPH0640903A (ja)	1994-02-15	脂肪酸含有治療剤
EP0246734B1 (fr)	1991-01-30	Composition contenant du fer et procédé de traitement du cancer
EP0437520B1 (fr)	1992-04-15	Triglyceride et composition nutritionnelle la comprenant
JPH0761954B2 (ja)	1995-07-05	コレステロール低下または上昇抑制剤
EP0201159A2 (fr)	1986-11-12	Compositions pharmaceutiques et diététiques contenant des acides linoléniques pour le traitement de l'hypertrophie prostatique bénigne
JPS6216415A (ja)	1987-01-24	月経前症候群治療用医薬組成物およびその治療方法
US6274751B1 (en)	2001-08-14	Wax esters enriched in ω-3 unsaturated fatty acids, their preparation and their use
JPH02503792A (ja)	1990-11-08	副腎白質ジストロフィーを治療するための医薬組成物
US4908162A (en)	1990-03-13	Method of making triple bonded unsaturated fatty acids

CA1239587A - Compose d'acides gras pour abaisser les taux de cholesterol et de triglycerides sanguins - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (4)

Publications (1)

Family

ID=27067902

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (56)

Family Cites Families (9)

Cited By (1)

Also Published As

Similar Documents

Legal Events